Benralizumab - A humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - A novel approach for the treatment of asthma

Aasia Ghazi, Anita Trikha, William Calhoun

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Introduction: Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. Areas covered: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. Expert opinion: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.

Original languageEnglish
Pages (from-to)113-118
Number of pages6
JournalExpert Opinion on Biological Therapy
Volume12
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Antibody-Dependent Cell Cytotoxicity
Cytotoxicity
Interleukin-5
Asthma
Antibodies
Eosinophils
Interleukin-5 Receptors
Monoclonal Antibodies
Pharmacodynamics
Pharmacokinetics
Expert Testimony
Neutralizing Antibodies
benralizumab

Keywords

  • Asthma
  • Benralizumab
  • IL-5
  • IL-5Rα
  • MEDI-563

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

@article{4018fd39abaf49cf874884b17a21f78c,
title = "Benralizumab - A humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - A novel approach for the treatment of asthma",
abstract = "Introduction: Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. Areas covered: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. Expert opinion: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.",
keywords = "Asthma, Benralizumab, IL-5, IL-5Rα, MEDI-563",
author = "Aasia Ghazi and Anita Trikha and William Calhoun",
year = "2012",
month = "1",
doi = "10.1517/14712598.2012.642359",
language = "English",
volume = "12",
pages = "113--118",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Benralizumab - A humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - A novel approach for the treatment of asthma

AU - Ghazi, Aasia

AU - Trikha, Anita

AU - Calhoun, William

PY - 2012/1

Y1 - 2012/1

N2 - Introduction: Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. Areas covered: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. Expert opinion: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.

AB - Introduction: Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. Areas covered: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. Expert opinion: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.

KW - Asthma

KW - Benralizumab

KW - IL-5

KW - IL-5Rα

KW - MEDI-563

UR - http://www.scopus.com/inward/record.url?scp=84055199162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055199162&partnerID=8YFLogxK

U2 - 10.1517/14712598.2012.642359

DO - 10.1517/14712598.2012.642359

M3 - Article

C2 - 22136436

AN - SCOPUS:84055199162

VL - 12

SP - 113

EP - 118

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 1

ER -